A randomised controlled trial of Standard Of Care versus RadioAblaTion in Early Stage HepatoCellular Carcinoma (SOCRATES HCC).
Early-stage hepatocellular carcinoma
SABR
SBRT
Stereotactic ablative radiotherapy
Thermal ablation
Transarterial therapies
Treatment stage migration
Journal
BMC cancer
ISSN: 1471-2407
Titre abrégé: BMC Cancer
Pays: England
ID NLM: 100967800
Informations de publication
Date de publication:
08 Jul 2024
08 Jul 2024
Historique:
received:
30
04
2024
accepted:
11
06
2024
medline:
8
7
2024
pubmed:
8
7
2024
entrez:
7
7
2024
Statut:
epublish
Résumé
Therapeutic options for early-stage hepatocellular carcinoma (HCC) in individual patients can be limited by tumor and location, liver dysfunction and comorbidities. Many patients with early-stage HCC do not receive curative-intent therapies. Stereotactic ablative body radiotherapy (SABR) has emerged as an effective, non-invasive HCC treatment option, however, randomized evidence for SABR in the first line setting is lacking. Trans-Tasman Radiation Oncology Group (TROG) 21.07 SOCRATES-HCC is a phase II, prospective, randomised trial comparing SABR to other current standard of care therapies for patients with a solitary HCC ≤ 8 cm, ineligible for surgical resection or transplantation. The study is divided into 2 cohorts. Cohort 1 will compromise 118 patients with tumors ≤ 3 cm eligible for thermal ablation randomly assigned (1:1 ratio) to thermal ablation or SABR. Cohort 2 will comprise 100 patients with tumors > 3 cm up to 8 cm in size, or tumors ≤ 3 cm ineligible for thermal ablation, randomly assigned (1:1 ratio) to SABR or best other standard of care therapy including transarterial therapies. The primary objective is to determine whether SABR results in superior freedom from local progression (FFLP) at 2 years compared to thermal ablation in cohort 1 and compared to best standard of care therapy in cohort 2. Secondary endpoints include progression free survival, overall survival, adverse events, patient reported outcomes and health economic analyses. The SOCRATES-HCC study will provide the first randomized, multicentre evaluation of the efficacy, safety and cost effectiveness of SABR versus other standard of care therapies in the first line treatment of unresectable, early-stage HCC. It is a broad, multicentre collaboration between hepatology, interventional radiology and radiation oncology groups around Australia, coordinated by TROG Cancer Research. anzctr.org.au, ACTRN12621001444875, registered 21 October 2021.
Sections du résumé
BACKGROUND
BACKGROUND
Therapeutic options for early-stage hepatocellular carcinoma (HCC) in individual patients can be limited by tumor and location, liver dysfunction and comorbidities. Many patients with early-stage HCC do not receive curative-intent therapies. Stereotactic ablative body radiotherapy (SABR) has emerged as an effective, non-invasive HCC treatment option, however, randomized evidence for SABR in the first line setting is lacking.
METHODS
METHODS
Trans-Tasman Radiation Oncology Group (TROG) 21.07 SOCRATES-HCC is a phase II, prospective, randomised trial comparing SABR to other current standard of care therapies for patients with a solitary HCC ≤ 8 cm, ineligible for surgical resection or transplantation. The study is divided into 2 cohorts. Cohort 1 will compromise 118 patients with tumors ≤ 3 cm eligible for thermal ablation randomly assigned (1:1 ratio) to thermal ablation or SABR. Cohort 2 will comprise 100 patients with tumors > 3 cm up to 8 cm in size, or tumors ≤ 3 cm ineligible for thermal ablation, randomly assigned (1:1 ratio) to SABR or best other standard of care therapy including transarterial therapies. The primary objective is to determine whether SABR results in superior freedom from local progression (FFLP) at 2 years compared to thermal ablation in cohort 1 and compared to best standard of care therapy in cohort 2. Secondary endpoints include progression free survival, overall survival, adverse events, patient reported outcomes and health economic analyses.
DISCUSSION
CONCLUSIONS
The SOCRATES-HCC study will provide the first randomized, multicentre evaluation of the efficacy, safety and cost effectiveness of SABR versus other standard of care therapies in the first line treatment of unresectable, early-stage HCC. It is a broad, multicentre collaboration between hepatology, interventional radiology and radiation oncology groups around Australia, coordinated by TROG Cancer Research.
TRIAL REGISTRATION
BACKGROUND
anzctr.org.au, ACTRN12621001444875, registered 21 October 2021.
Identifiants
pubmed: 38973009
doi: 10.1186/s12885-024-12504-2
pii: 10.1186/s12885-024-12504-2
doi:
Types de publication
Journal Article
Clinical Trial Protocol
Randomized Controlled Trial
Clinical Trial, Phase II
Comparative Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
813Informations de copyright
© 2024. The Author(s).
Références
Petrick JL, Braunlin M, Laversanne M, Valery PC, Bray F, McGlynn KA. International trends in liver cancer incidence, overall and by histologic subtype, 1978–2007. Int J Cancer. 2016;139(7):1534–45.
doi: 10.1002/ijc.30211
pubmed: 27244487
pmcid: 5310166
European Association for the Study of the Liver, Electronic address eee, European Association for the Study of the L. EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2018;69(1):182–236.
doi: 10.1016/j.jhep.2018.03.019
Reig M, Forner A, Rimola J, Ferrer-Fábrega J, Burrel M, Garcia-Criado A, et al. BCLC strategy for prognosis prediction and treatment recommendation Barcelona Clinic Liver Cancer (BCLC) staging system. The 2022 update. J Hepatol. 2022;76(3):681–93. https://doi.org/10.1016/j.jhep.2021.11.018 .
Marrero JA, Kulik LM, Sirlin CB, Zhu AX, Finn RS, Abecassis MM, et al. Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American association for the study of liver diseases. Hepatology. 2018;68(2):723–50.
doi: 10.1002/hep.29913
pubmed: 29624699
Devaki P, Wong RJ, Marupakula V, Nangia S, Nguyen L, Ditah IC, et al. Approximately one-half of patients with early-stage hepatocellular carcinoma meeting Milan criteria did not receive local tumor destructive or curative surgery in the post-MELD exception era. Cancer. 2014;120(11):1725–32.
doi: 10.1002/cncr.28639
pubmed: 24590359
Wu X, Lokken RP, Mehta N. Optimal treatment for small HCC (<3 cm): Resection, liver transplantation, or locoregional therapy? JHEP Rep. 2023;5(8):100781.
doi: 10.1016/j.jhepr.2023.100781
pubmed: 37456674
pmcid: 10339255
Lu DS, Raman SS, Limanond P, Aziz D, Economou J, Busuttil R, et al. Influence of large peritumoral vessels on outcome of radiofrequency ablation of liver tumors. J Vasc Interv Radiol. 2003;14(10):1267–74.
doi: 10.1097/01.RVI.0000092666.72261.6B
pubmed: 14551273
Kuvshinoff BW, Ota DM. Radiofrequency ablation of liver tumors: influence of technique and tumor size. Surgery. 2002;132(4):605–11; discussion 11-2.
doi: 10.1067/msy.2002.127545
pubmed: 12407343
Jeong Y, Lee KJ, Lee SJ, Shin YM, Kim MJ, Lim YS, et al. Radiofrequency ablation versus stereotactic body radiation therapy for small (</= 3 cm) hepatocellular carcinoma: A retrospective comparison analysis. J Gastroenterol Hepatol. 2021.
Loo K, Woodman RJ, Bogatic D, Muller KR, Chandran V, Chinnaratha MA, et al. Treatment stage migration for early HCCs and its impact on outcomes- a multi-centre study. Hepatology. 2020;72(S1):655A-A.
Roberts SK, Gazzola A, Lubel J, Gow P, Bell S, Nicoll A, et al. Treatment choice for early-stage hepatocellular carcinoma in real-world practice: impact of treatment stage migration to transarterial chemoembolization and treatment response on survival. Scand J Gastroenterol. 2018;53(10–11):1368–75.
doi: 10.1080/00365521.2018.1517277
pubmed: 30394145
Dobrzycka M, Spychalski P, Rostkowska O, Wilczyński M, Kobiela P, Grąt M, et al. Stereotactic body radiation therapy for early-stage hepatocellular carcinoma - a systematic review on outcome. Acta Oncol. 2019;58(12):1706–13.
doi: 10.1080/0284186X.2019.1657942
pubmed: 31464155
Rim CH, Kim HJ, Seong J. Clinical feasibility and efficacy of stereotactic body radiotherapy for hepatocellular carcinoma: a systematic review and meta-analysis of observational studies. Radiother Oncol. 2019;131:135–44.
doi: 10.1016/j.radonc.2018.12.005
pubmed: 30773180
Dobrzycka M, Spychalski P, Rostkowska O, Wilczynski M, Kobiela P, Grat M, et al. Stereotactic body radiation therapy for early-stage hepatocellular carcinoma - a systematic review on outcome. Acta Oncol. 2019;58(12):1706–13.
doi: 10.1080/0284186X.2019.1657942
pubmed: 31464155
Wahl DR, Stenmark MH, Tao Y, Pollom EL, Caoili EM, Lawrence TS, et al. Outcomes after stereotactic body radiotherapy or radiofrequency ablation for hepatocellular carcinoma. J Clin Oncol. 2016;34(5):452–9.
doi: 10.1200/JCO.2015.61.4925
pubmed: 26628466
Kim N, Cheng J, Jung I, Liang J, Shih YL, Huang WY, et al. Stereotactic body radiation therapy vs. radiofrequency ablation in Asian patients with hepatocellular carcinoma. J Hepatol. 2020;73(1):121–9.
doi: 10.1016/j.jhep.2020.03.005
pubmed: 32165253
Kim TH, Koh YH, Kim BH, Kim MJ, Lee JH, Park B, et al. Proton beam radiotherapy vs. radiofrequency ablation for recurrent hepatocellular carcinoma: a randomized phase III trial. J Hepatol. 2021;74(3):603–12.
doi: 10.1016/j.jhep.2020.09.026
pubmed: 33031846
Mendez Romero A, van der Holt B, Willemssen F, de Man RA, Heijmen BJM, Habraken S, et al. Transarterial chemoembolization with drug-eluting beads versus stereotactic body radiation therapy for hepatocellular carcinoma: outcomes from a multicenter, randomized, phase 2 trial (the TRENDY Trial). Int J Radiat Oncol Biol Phys. 2023;117(1):45–52.
doi: 10.1016/j.ijrobp.2023.03.064
pubmed: 37037359
Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 2010;30(1):52–60.
doi: 10.1055/s-0030-1247132
pubmed: 20175033
Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–47.
doi: 10.1016/j.ejca.2008.10.026
pubmed: 19097774
Llovet JM, Lencioni R. mRECIST for HCC: Performance and novel refinements. J Hepatol. 2020;72(2):288–306.
doi: 10.1016/j.jhep.2019.09.026
pubmed: 31954493
Llovet JM, Villanueva A, Marrero JA, Schwartz M, Meyer T, Galle PR, et al. Trial design and endpoints in hepatocellular carcinoma: AASLD consensus conference. Hepatology. 2021;73(Suppl 1):158–91.
doi: 10.1002/hep.31327
pubmed: 32430997
Roberts SK, Gazzola A, Lubel J, Gow P, Bell S, Nicoll A, et al. Treatment choice for early-stage hepatocellular carcinoma in real-world practice: impact of treatment stage migration to transarterial chemoembolization and treatment response on survival. Scand J Gastroenterol. 2018;53(10–11):1368–75.
doi: 10.1080/00365521.2018.1517277
pubmed: 30394145
Sapir E, Tao Y, Schipper MJ, Bazzi L, Novelli PM, Devlin P, et al. Stereotactic body radiation therapy as an alternative to transarterial chemoembolization for hepatocellular carcinoma. Int J Radiat Oncol Biol Phys. 2018;100(1):122–30.
doi: 10.1016/j.ijrobp.2017.09.001
pubmed: 29066120
Baek MY, Yoo JJ, Jeong SW, Jang JY, Kim YK, Jeong SO, et al. Clinical outcomes of patients with a single hepatocellular carcinoma less than 5 cm treated with transarterial chemoembolization. Korean J Intern Med. 2019;34(6):1223–32.
doi: 10.3904/kjim.2018.058
pubmed: 30360019